ALDH1A1 and neoplasm: In marked contrast to Bevacizumab treatment alone, the percentage of ALDH1+ cells of Bevacizumab + SHH002-hu1 group evidently decreased in MDA-MB-231/MDA-MB-468 tumor tissues (Fig. 5e).